Login

$AIDX SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Date of Report (Date of earliest event reported): November 16, 2026

21 Oct 2026 DEFINITIVE ADDITIONAL MATERIALS
21 Oct 2026 DEFINITIVE PROXY STATEMENT
06 Oct 2026 PRELIMINARY PROXY STATEMENT
18 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

As previously disclosed, on August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) convened its annual meeting of stockholders of the Company (the “Annual Meeting”). At the Annual Meeting, the Company did not receive a sufficient number of...

10 Sep 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

02 Sep 2026 8-K: Regulation FD Disclosure

Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur...

19 Aug 2026 DEFINITIVE ADDITIONAL MATERIALS
19 Aug 2026 8-K: Submission of Matters to a Vote of Security Holders

On August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) held an annual meeting of stockholders of the Company (the “Annual Meeting”) via live webcast. Holders of shares of the Company’s common stock at the close of business on June 22, 2...

17 Aug 2026 PROSPECTUS SUPPLEMENT
17 Aug 2026 PROSPECTUS SUPPLEMENT
17 Aug 2026 8-K: Results of Operations and Financial Condition

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

14 Aug 2026 QUARTERLY REPORT
05 Aug 2026 8-K: Regulation FD Disclosure

Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur...

22 Jul 2026 8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule

This Standstill Agreement (this “Agreement”) is entered into as of July 16, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and 20/20 Biolabs, Inc., a Delaware corpora...

01 Jul 2026 8-K: Regulation FD Disclosure

Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur...

23 Jun 2026 DEFINITIVE ADDITIONAL MATERIALS
23 Jun 2026 Proxy statement: annual meeting on August 18, 2026
01 Jun 2026 PRELIMINARY PROXY STATEMENT
26 May 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

This Amendment No. 1 to Amended and Restated Bylaws (this “Amendment”) of 20/20 Biolabs, Inc., a Delaware corporation (formerly 20/20 GeneSystems, Inc.) (the “Corporation”), is effective as of May 19, 2026 (the “Effective Date”).

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support